Proteologics

Proteologics is an integrated biotechnology company that specializes in the ubiquitin system. The company develops a new class of small molecule drugs against major diseases based on ubiquitin ligase inhibitors. Proteologics combines world-class knowledge of the ubiquitin system with a unique platform that helps to discover the involvement of ubiquitin ligases in diseases and develop inhibitors to them.

Proteologics pursues programs in several diseases areas, with anti-virals being the most advanced. The company is currently developing small-molecule inhibitors to the first of several E3 ubiquitin-ligases that it discovered to be essential to the life cycle of HIV and other major viruses. Dramatically reducing virus infectivity, these inhibitors are anticipated to be much more effective against the emergence of viral resistance, the most acute problem in HIV therapy today. Furthermore, initial evidence indicates that they are also effective against other enveloped viruses, raising the prospect of an eventual broad-spectrum anti-viral drug.

Proteologics is an integrated biotechnology company and is closely associated with some of the pioneering researchers of the ubiquitin system.

Israel Headquarters
Proteologics, Ltd.
2 Holzman Street
Weizmann Science Park
Rehovot, Israel 76124
Tel: +972-8-947-5666
Fax: +972-8-947-5999
 

US Headquarters
Proteologics, Inc.
40 Ramland Road South, Suite 10
Orangeburg, New York 10962

web: http://proteologics.com